<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10320062</article-id>
    <article-id pub-id-type="pmid">37166953</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkad375</article-id>
    <article-id pub-id-type="publisher-id">gkad375</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Web Server Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>OnTarget: <italic toggle="yes">in silico</italic> design of MiniPromoters for targeted delivery of expression</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5969-3054</contrib-id>
        <name>
          <surname>Fornes</surname>
          <given-names>Oriol</given-names>
        </name>
        <!--oriol.fornes@gmail.com-->
        <aff><institution>Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, BC Children's Hospital Research Institute, University of British Columbia</institution>, <addr-line>Vancouver</addr-line>, <country country="CA">Canada</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Av-Shalom</surname>
          <given-names>Tamar V</given-names>
        </name>
        <aff><institution>Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, BC Children's Hospital Research Institute, University of British Columbia</institution>, <addr-line>Vancouver</addr-line>, <country country="CA">Canada</country></aff>
        <aff><institution>Department of Cell and Systems Biology, University of Toronto</institution>, <addr-line>Toronto</addr-line>, <country country="CA">Canada</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Korecki</surname>
          <given-names>Andrea J</given-names>
        </name>
        <aff><institution>Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, BC Children's Hospital Research Institute, University of British Columbia</institution>, <addr-line>Vancouver</addr-line>, <country country="CA">Canada</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Farkas</surname>
          <given-names>Rachelle A</given-names>
        </name>
        <aff><institution>Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, BC Children's Hospital Research Institute, University of British Columbia</institution>, <addr-line>Vancouver</addr-line>, <country country="CA">Canada</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Arenillas</surname>
          <given-names>David J</given-names>
        </name>
        <aff><institution>Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, BC Children's Hospital Research Institute, University of British Columbia</institution>, <addr-line>Vancouver</addr-line>, <country country="CA">Canada</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5127-5459</contrib-id>
        <name>
          <surname>Mathelier</surname>
          <given-names>Anthony</given-names>
        </name>
        <aff><institution>Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo</institution>, <addr-line>Oslo</addr-line>, <country country="NO">Norway</country></aff>
        <aff><institution>Department of Medical Genetics, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital</institution>, <addr-line>Oslo</addr-line>, <country country="NO">Norway</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Simpson</surname>
          <given-names>Elizabeth M</given-names>
        </name>
        <aff><institution>Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, BC Children's Hospital Research Institute, University of British Columbia</institution>, <addr-line>Vancouver</addr-line>, <country country="CA">Canada</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6098-6412</contrib-id>
        <name>
          <surname>Wasserman</surname>
          <given-names>Wyeth W</given-names>
        </name>
        <!--wyeth@cmmt.ubc.ca-->
        <aff><institution>Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, BC Children's Hospital Research Institute, University of British Columbia</institution>, <addr-line>Vancouver</addr-line>, <country country="CA">Canada</country></aff>
        <xref rid="COR2" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Email: <email>oriol.fornes@gmail.com</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Wyeth W. Wasserman. Tel: +1 604 875 3812; Fax: +1 604 875 3819; Email: <email>wyeth@cmmt.ubc.ca</email></corresp>
      <fn id="FN1">
        <p>The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>7</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-05-11">
      <day>11</day>
      <month>5</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>11</day>
      <month>5</month>
      <year>2023</year>
    </pub-date>
    <volume>51</volume>
    <issue>W1</issue>
    <fpage>W379</fpage>
    <lpage>W386</lpage>
    <history>
      <date date-type="accepted">
        <day>27</day>
        <month>4</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>24</day>
        <month>4</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>28</day>
        <month>3</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkad375.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>MiniPromoters, or compact promoters, are short DNA sequences that can drive expression in specific cells and tissues. While broadly useful, they are of high relevance to gene therapy due to their role in enabling precise control of where a therapeutic gene will be expressed. Here, we present OnTarget (<ext-link xlink:href="http://ontarget.cmmt.ubc.ca" ext-link-type="uri">http://ontarget.cmmt.ubc.ca</ext-link>), a webserver that streamlines the MiniPromoter design process. Users only need to specify a gene of interest or custom genomic coordinates on which to focus the identification of promoters and enhancers, and can also provide relevant cell-type-specific genomic evidence (e.g. accessible chromatin regions, histone modifications, etc.). OnTarget combines the provided data with internal data to identify candidate promoters and enhancers and design MiniPromoters. To illustrate the utility of OnTarget, we designed and characterized two MiniPromoters targeting different cell populations relevant to Parkinson Disease.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <caption>
            <p>OnTarget (<ext-link xlink:href="http://ontarget.cmmt.ubc.ca" ext-link-type="uri">http://ontarget.cmmt.ubc.ca</ext-link>) is a webserver for the design of cell-type-specific MiniPromoters from genomic evidence provided by users. MiniP, MiniPromoter.</p>
          </caption>
          <graphic xlink:href="gkad375figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Genome Canada and the Canadian Institutes of Health Research</institution>
          </institution-wrap>
        </funding-source>
        <award-id>255ONT</award-id>
        <award-id>BOP-149430</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Science and Engineering Research Council of Canada</institution>
          </institution-wrap>
        </funding-source>
        <award-id>RGPIN-2017-06824</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Weston Brain Institute</institution>
            <institution-id institution-id-type="DOI">10.13039/100012479</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="8"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>MiniPromoters, or compact promoters, are short <italic toggle="yes">cis</italic>-regulatory sequences that control the expression of adjacent DNA in specific cells or tissues (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>). The development of compact promoters is an active area of research in molecular biology, but recently, there has been a renewed interest due to their potential for therapeutic gene delivery (<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>). The field of gene therapy is increasingly focusing on improving expression specificity to minimize off-target expression and mitigate adverse events such as immune responses. This trend has been in part motivated by the adoption of recombinant adeno-associated virus (rAAV) vectors, which have low immunogenicity (<xref rid="B5" ref-type="bibr">5</xref>), allow for long-term expression (<xref rid="B6" ref-type="bibr">6</xref>), and can be engineered to target specific cell types, tissues, or organs (<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>). However, a limitation of rAAV vectors is their DNA payload capacity (<xref rid="B9" ref-type="bibr">9</xref>), highlighting the importance of promoter compactness in gene therapy research.</p>
    <p>For decades, researchers have focused on designing compact promoters to efficiently transduce the brain, heart, liver, and retina, including specific cell types within these organs (Table S1). For instance, we have developed, and refined over the years, a manual approach to design human MiniPromoters, which were then characterized for specificity in the central nervous systems of mice and primates (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B10" ref-type="bibr">10–14</xref>). The process involves selecting a gene with relevant expression in the target cells or tissue (identified from the literature or single-cell RNA-seq (<xref rid="B15" ref-type="bibr">15</xref>)), defining a genomic window around the gene for analysis, identifying candidate <italic toggle="yes">cis</italic>-regulatory regions (CRRs) within the window based on genomic evidence (from experimental assays measuring different epigenetic properties) and conservation (<xref rid="B16" ref-type="bibr">16</xref>), combining a subset of the resulting CRRs into a MiniPromoter, and characterizing the MiniPromoter <italic toggle="yes">in vivo</italic>.</p>
    <p>To meet the increasing demand for compact promoters with user-relevant specificity, we have developed OnTarget, a webserver that streamlines the MiniPromoter design process. Users only need to specify a gene of interest or custom genomic coordinates on which to focus the identification of CRRs, and can also provide relevant cell-type-specific genomic evidence. OnTarget uses this information, as well as internal data, to identify candidate CRRs and suggest MiniPromoter designs. To illustrate the utility of OnTarget, we designed two MiniPromoters to target two cell populations relevant to Parkinson Disease. For comparison, we additionally characterized two manual MiniPromoters designed from the same genes. All MiniPromoters were experimentally validated for regional specificity, demonstrating that OnTarget designs could effectively drive on target expression.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>MATERIALS AND METHODS</title>
    <sec id="SEC2-1">
      <title>Implementation</title>
      <p>OnTarget is a webserver deployed as a Node.js application that helps users identify CRRs and design MiniPromoters. It communicates with a REST API that accesses an underlying data repository storing genomic information and a Python framework encompassing the main functionalities of OnTarget (Figure <xref rid="F1" ref-type="fig">1</xref>). Details about the identification of CRRs, MiniPromoter design process, and interaction with the webserver are provided below, and in the Results section ‘OnTarget walkthrough’.</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Schematic representation of the OnTarget workflow. OnTarget accepts input from the user such as genomic evidence and returns CRRs and MiniPromoters. The identification of CRRs and MiniPromoter design process is informed with internal data from GUD, a database unifying gene definitions, multi-species conservation and repetitive elements from the UCSC Genome Browser (<xref rid="B17" ref-type="bibr">17</xref>). CRR, <italic toggle="yes">cis</italic>-regulatory region; GUD, Genomic Unification Database.</p>
        </caption>
        <graphic xlink:href="gkad375fig1" position="float"/>
      </fig>
      <p>The underlying data repository, named GUD (Genomic Unification Database), comprises two MySQL databases: one for storing human information related to the hg19 genome assembly and the other for mouse (mm10 genome assembly). Both databases were populated with data from the UCSC Genome Browser (<xref rid="B17" ref-type="bibr">17</xref>) (Table S2), which were unified for improved efficiency. These include RefSeq gene definitions (<xref rid="B18" ref-type="bibr">18</xref>), which, for each gene, cover its name, symbol, transcription start and end positions, coding start and end positions, exons start and end positions, and strand location, conservation values from the multiz alignment of multiple vertebrate species (<xref rid="B16" ref-type="bibr">16</xref>), and repetitive elements identified by RepeatMasker such as short interspersed nuclear elements (SINEs), which include ALUs, long interspersed nuclear elements (LINEs), long terminal repeat elements (LTRs), which include retroposons, DNA repeat elements, micro-satellites, low complexity repeats, satellite repeats, RNA repeats (RNA, tRNA, rRNA, snRNA, scRNA and srpRNA), and other repeats (e.g. class Rolling Circle).</p>
      <p>The Python framework interacts with the REST API of GUD to extract genomic information and inform the identification of CRRs and MiniPromoter design process. It has three main entry points: (i) ‘gene2interval’ takes as input a gene and a genome assembly (i.e. ‘hg19’ or ‘mm10’) and returns a genomic window for analysis based on either the untranslated regions (UTRs) of the closest upstream and downstream genes or distance (in kb) around the gene body; (ii) ‘interval2regions’ takes as input a genomic window, a genome assembly, and genomic evidence (if provided), and returns a list of CRRs labelled as promoters or enhancers and (iii) ‘regions2minipromoter’ takes as input promoters and enhancers and returns MiniPromoter designs.</p>
    </sec>
    <sec id="SEC2-2">
      <title>Identification of CRRs and conserved regions</title>
      <p>For a given genomic window, we first initialize a NumPy array (<xref rid="B19" ref-type="bibr">19</xref>) of the same length using conservation values from GUD, which range from 0 to 1. If conservation is not enabled, the array is initialized with zeroes. Each array position, which corresponds to a nucleotide, is further scored positively (i.e. +1) for each type of genomic evidence that it overlaps with, and, if conservation is enabled, if it overlaps with conserved regions (details are provided below). For instance, a conserved nucleotide that is located within an accessible chromatin region, and supported by the histone modification H3K27ac (a hallmark of active enhancers (<xref rid="B20" ref-type="bibr">20</xref>)), additionally receives a score of 3. However, if the same nucleotide is not conserved and does not overlap any genomic evidence, it does not receive an additional score. Then, if enabled, we mask nucleotides overlapping with either coding exons or repetitive elements from GUD (i.e. their scores in the array are set to 0). Next, we normalize the array scores between 0 and 1 using the ‘MinMaxScaler’ function from scikit-learn (<xref rid="B21" ref-type="bibr">21</xref>). Finally, to define CRRs, we identify blocks of ≥100 consecutive nucleotides with a score in the normalized array ≥0.5 (these values can be adjusted in the webserver). To label CRRs as promoters or enhancers, we determine their overlap with gene transcription start positions from GUD, which are used as source of transcription start sites (TSSs). For genes located on the reverse strand, we use transcription end positions as source of TSSs instead. If a CRR overlaps with a TSS, it is labelled as a promoter; otherwise, it is labelled as an enhancer.</p>
      <p>If enabled, conserved regions are identified in a similar way to CRRs. However, instead of the normalized array, we use a copy of the original NumPy array initialized with conservation values. Moreover, we set by default the number of consecutive nucleotides to identify conserved blocks to ≥10 and the score to ≥0.6 (like for CRRs, these values can be adjusted in the webserver). Finally, the system performs a second pass in which nearby conserved blocks are merged if their resulting score after merging, including the nucleotides within and between the blocks, would still be ≥ 0.6.</p>
    </sec>
    <sec id="SEC2-3">
      <title>MiniPromoter design process</title>
      <p>For each CRR labeled as promoter, five MiniPromoters are designed by placing it at the 3′ end and then adding CRRs labelled as enhancers, up to a maximum size of 1.9 kb (both the number of MiniPromoter designs and their size can be adjusted in the webserver). Upstream enhancers are added first, from more proximal (i.e. closer to the promoter) to more distal (i.e. farther from the promoter), followed by downstream enhancers (also from more proximal to more distal). When the gene is on the reverse strand, however, downstream enhancers are added first, followed by upstream enhancers (in both cases from more proximal to more distal). If transcription factors (TFs) are specified, CRRs are filtered out so that the final designs only include promoters and enhancers featuring binding sites for those TFs. As a source for TF binding sites (TFBSs), we relied on the JASPAR 2020 TFBS predictions (<xref rid="B22" ref-type="bibr">22</xref>) from the UCSC Genome Browser (<xref rid="B17" ref-type="bibr">17</xref>). Moreover, if any restriction enzymes are specified, MiniPromoters whose sequence include sites for those restriction enzymes are filtered out.</p>
    </sec>
    <sec id="SEC2-4">
      <title>LiftOver</title>
      <p>As per the recommendations from the UCSC Genome Browser, we executed LiftOver (<xref rid="B23" ref-type="bibr">23</xref>) to remap coordinates between the genome assemblies of two different organisms by setting the minimum nucleotide ratio for remapping (i.e. option ‘-minMatch’) to 0.1. For remapping coordinates between two genome assemblies of the same organism, we executed LiftOver with default parameters.</p>
    </sec>
    <sec id="SEC2-5">
      <title>Manual MiniPromoter designs</title>
      <p>We have previously described a manual bioinformatics pipeline to design MiniPromoters (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B14" ref-type="bibr">14</xref>). The process starts with the selection of a gene with relevant expression in the target cells or tissue (e.g. a marker from single-cell RNA-seq data). Then, the promoter and enhancers of the gene are identified by integrating different types of genomic evidence associated with CRRs and visualizing them in a genome browser such as IGV (<xref rid="B24" ref-type="bibr">24</xref>). These include nascent transcription from CAGE (<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref>) and GRO-seq (<xref rid="B27" ref-type="bibr">27</xref>), chromatin accessibility from DNase-seq (<xref rid="B28" ref-type="bibr">28</xref>) or ATAC-seq (<xref rid="B29" ref-type="bibr">29</xref>), ChIP-seq (<xref rid="B30" ref-type="bibr">30</xref>) of histone modifications and TFBSs, computational predictions from ENCODE (<xref rid="B31" ref-type="bibr">31</xref>), and multi-species conservation (<xref rid="B16" ref-type="bibr">16</xref>). Identification of promoters and enhancers can be limited by the proximity of nearby genes, regulatory confinements imposed by topologically associating domains (<xref rid="B32" ref-type="bibr">32</xref>), or by defining a custom genomic window. Next, MiniPromoters are designed by placing the promoter of the gene at the 3′ end and then adding enhancers as needed following the same criteria as described above for OnTarget. Finally, the MiniPromoter sequences are analyzed to detect the presence of undesired restriction sites using tools such as NEBcutter (<xref rid="B33" ref-type="bibr">33</xref>).</p>
    </sec>
    <sec id="SEC2-6">
      <title>OnTarget MiniPromoter designs</title>
      <p>As genomic evidence for designing the <italic toggle="yes">ADORA2A</italic> MiniPromoter, we downloaded ATAC-seq data (in bigWig format) of post-mortem human (hg19) neurons of the accumbens nucleus and putamen (<xref rid="B34" ref-type="bibr">34</xref>) (GEO accessions: GSM2546440, GSM2546463, GSM2546465, GSM2546489, GSM2546535). We reformatted the files from bigWig to bedGraph using bigWigToBedGraph (<xref rid="B35" ref-type="bibr">35</xref>) and then processed them one-by-one using MACS2 bdgpeakcall (<xref rid="B36" ref-type="bibr">36</xref>) (version 2.1.4) with default parameters. The resulting peaks were pooled into a single file and remapped to mm10. Next, we downloaded H3K4me1, H3K4me3, H3K36me3, and RNA polymerase II ChIP-seq data (in bigWig format) of 8 weeks-old mice (mm9) saline-treated accumbens nucleus samples (<xref rid="B37" ref-type="bibr">37</xref>) (GEO accessions: GSM1050343, GSM1050344, GSM1050345, GSM1050349, GSM1050350, GSM1050351, GSM1050355, GSM1050356, GSM1050357, GSM1050368, GSM1050369, GSM1050370). As with the ATAC-seq data, bigWig files were reformatted into bedGraph format and individually processed using MACS2, and the resulting peaks were pooled into individual files, one for each factor, and remapped to mm10. Finally, we downloaded H3K27ac ChIP-seq peaks of medium spiny neurons (MSNs) of the mouse striatum (mm9) (<xref rid="B38" ref-type="bibr">38</xref>) (GEO accession: GSM2230267), which we remapped to mm10.</p>
      <p>For the <italic toggle="yes">PITX3</italic> MiniPromoter, we downloaded DNase-seq and ChIP-seq peaks of histone marks H3K4me1, H3K4me3, H3K9ac, and H3K27ac of midbrain samples of newborn mice (mm10) (<xref rid="B31" ref-type="bibr">31</xref>) (ENCODE accessions: ENCFF588FLL, ENCFF741TQE, ENCFF903IBK, ENCFF770SEL, ENCFF818XLK, ENCFF991JUZ). Peaks from the two DNase-seq datasets were pooled into a single file.</p>
      <p>In OnTarget, a key hyperparameter is the minimum score threshold that is used to identify CRRs. We set this threshold to the score of the nucleotide ranked at the top fifth percentile within the genomic window, which corresponds to ∼0.555 when designing the <italic toggle="yes">ADORA2A</italic> MiniPromoter and ∼0.414 for the <italic toggle="yes">PITX3</italic> MiniPromoter.</p>
    </sec>
    <sec id="SEC2-7">
      <title>Experimental validation</title>
      <p>MiniPromoters were characterized in mice for their ability to drive expression in the D2-type MSNs of the striatum (<italic toggle="yes">ADORA2A</italic>) or the dopaminergic neurons of the substantia nigra (<italic toggle="yes">PITX3</italic>) following a well-established protocol that we have previously used to characterize hundreds of MiniPromoters (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B14" ref-type="bibr">14</xref>). Each MiniPromoter was synthesized (GenScript), cloned into a rAAV genome plasmid driving the expression of emerald green fluorescent protein (EmGFP), and packaged into either AAV9 (Ple253) or rAAV-PHP.B (Ple355, Ple388, Ple389) capsids for widespread brain transduction (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B39" ref-type="bibr">39</xref>). Mice were injected intravenously, either via the superficial temporal vein at postnatal day 4 (rAAV9), or via the tail vein in adult mice (rAAV-PHP.B). Four weeks following injection, a minimum of three mice per MiniPromoter were given a lethal dose of avertin and perfused transcardially, after which brains were harvested. Brain tissue was cryosectioned at 20 μM either sagittally (<italic toggle="yes">ADORA2A</italic>) or coronally (<italic toggle="yes">PITX3</italic>), mounted directly onto slides, and stained with anti-GFP (GFP-1020, Aves Labs; Alexa Fluor 488, Life Technologies) and Hoechst (Sigma-Aldrich). At least two mice per MiniPromoter were assessed, and unique expression patterns were determined by fluorescent microscopy and image analysis.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>RESULTS</title>
    <sec id="SEC3-1">
      <title>OnTarget walkthrough</title>
      <p>The webserver guides users through the identification of candidate CRRs and MiniPromoter design process step-by-step:</p>
      <list list-type="bullet">
        <list-item>
          <p>Select either the human (i.e. ‘hg19’) or mouse (i.e. ‘mm10’) genome assembly. If mm10 is selected, specify whether the final CRRs should be remapped to hg19 using LiftOver.</p>
        </list-item>
        <list-item>
          <p>Select a gene with an on target expression pattern with which to define a genomic window for analysis, or specify ‘Custom Coordinates’. If a gene is selected, define the genomic window based on the UTRs of the closest upstream and downstream genes (i.e. ‘Gene to Gene’) or distance (i.e. ‘±<italic toggle="yes">n</italic> kb from Gene’). The maximum size of genomic windows is limited to 250 kb.</p>
        </list-item>
        <list-item>
          <p>Upload genomic evidence relevant to the target cells in BED format. Uploaded data will be deleted from the webserver after 1 month.</p>
        </list-item>
        <list-item>
          <p>Click the button ‘Get Regulatory Regions’.</p>
        </list-item>
      </list>
      <p>Users can additionally specify advanced parameters related to the identification of CRRs. We have set the default values for these parameters based on our experience, and expect them to be appropriate for most cases. Upon clicking the button ‘Get Regulatory Regions’, OnTarget will redirect users to a new page, where they will have to wait briefly (typically &lt;1 min) while it identifies and returns the CRRs. The resulting CRRs are labelled as promoters or enhancers, and include useful information such as the genomic coordinates, score, and size. Next, users can design their own MiniPromoters by selecting at least one promoter from the list of CRRs and clicking the button ‘Download MiniPromoter’. Users can also click the button ‘Download Suggested MiniPromoters’ to have OnTarget automatically design and return MiniPromoters. Additionally, users can specify the number and size of the designed MiniPromoters, whether to prioritize the inclusion of CRRs with specific TFBSs, or to avoid specific restriction sites.</p>
    </sec>
    <sec id="SEC3-2">
      <title>Case examples</title>
      <p>To demonstrate the utility of OnTarget, we applied it to design two MiniPromoters based on the genes <italic toggle="yes">ADORA2A</italic> and <italic toggle="yes">PITX3</italic>. Both examples, including the genomic evidence used as input as well as the identified CRRs and MiniPromoter sequences, are accessible via dedicated pages on the OnTarget web server and can be downloaded by users.</p>
    </sec>
    <sec id="SEC3-3">
      <title><italic toggle="yes">ADORA2A</italic> MiniPromoter</title>
      <p>The <italic toggle="yes">ADORA2A</italic> gene was selected based on its well-established status as a marker of striatal D2-type MSNs (<xref rid="B40" ref-type="bibr">40</xref>), which are of therapeutic interest due to their contribution to the pathophysiology in Parkinson Disease (<xref rid="B41" ref-type="bibr">41</xref>). We downloaded publicly available ATAC-seq and ChIP-seq data of histone modifications H3K4me1, H3K4me3, H3K36me3, and H3K27ac and of RNA polymerase II from relevant samples, which were processed and remapped to mm10 (Methods). We then applied OnTarget to identify candidate CRRs of <italic toggle="yes">ADORA2A</italic> as follows: (i) we set the genome assembly to mm10 and specified to remap the identified CRRs to hg19; (ii) defined the genomic window within which to identify the CRRs based on a distance of ± 100 kb around the mouse gene (<italic toggle="yes">i.e</italic>. mm10:chr10:75216877–75434792); (iii) uploaded the genomic evidence and (iv) set the score threshold for identifying CRRs to ∼0.555 (a value that would return the top 5% of nucleotides). OnTarget returned 30 CRRs (Table S3), including RR13, one of two <italic toggle="yes">ADORA2A</italic> promoter-like CRRs that overlapped with a cluster of FANTOM5 TSSs characterized by robust and specific expression in striatal samples (<xref rid="B26" ref-type="bibr">26</xref>), and 20 enhancers overlapping with predicted TFBSs for the TFs RARB and SP9, which have been reported to regulate D2-type MSN genes (<xref rid="B42" ref-type="bibr">42</xref>,<xref rid="B43" ref-type="bibr">43</xref>). Upon examination, we applied OnTarget to combine CRRs 7, 13, 18 and 25 into the MiniPromoter ‘Ple389’, which had a length of 1344 bp and whose sequence did not contain sites for the restriction enzymes <italic toggle="yes">Asc</italic>l and <italic toggle="yes">Fse</italic>I, which were used for cloning. Finally, Ple389 was synthesized, cloned into an rAAV genome plasmid, packaged into rAAV, and characterized for its ability to drive cell-type-specific EmGFP expression in the striatum (Methods). For comparison, we also characterized Ple355, a MiniPromoter that we manually designed based on <italic toggle="yes">ADORA2A</italic> (Methods). Intravenous delivery of the capsids rAAV9 and its derivative rAAV-PHP.B ensure widespread transduction of brain cells (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B39" ref-type="bibr">39</xref>). Indeed, the results using the manual design Ple355 confirmed this widespread transduction, because the MiniPromoter directed ubiquitous expression throughout the brain (Figure <xref rid="F2" ref-type="fig">2</xref>, top-right panel). In contrast, the OnTarget design Ple389 showed strong and specific expression in the striatum (Figure <xref rid="F2" ref-type="fig">2</xref>, top-left panel), which is the location of the target D2-type MSNs.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p><italic toggle="yes">ADORA2A</italic>- (top panels) and <italic toggle="yes">PITX3</italic>-based (bottom panels) MiniPromoters designed either using OnTarget (left panels) or by manually identifying and combining CRRs potentially regulating the expression of each gene (right panels). MiniPromoters were characterized in mice for their ability to drive specific expression in the striatum (<italic toggle="yes">ADORA2A</italic>) or the substantia nigra (<italic toggle="yes">PITX3</italic>) using rAAV vectors (Methods). SN, substantia nigra; Str, striatum. Green, anti-GFP; blue, Hoechst.</p>
        </caption>
        <graphic xlink:href="gkad375fig2" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-4">
      <title><italic toggle="yes">PITX3</italic> MiniPromoter</title>
      <p>The <italic toggle="yes">PITX3</italic> gene was selected because it encodes a TF that plays a crucial role in the specification of dopaminergic neurons of the substantia nigra (<xref rid="B44" ref-type="bibr">44</xref>), whose loss is a hallmark of Parkinson Disease (<xref rid="B45" ref-type="bibr">45</xref>,<xref rid="B46" ref-type="bibr">46</xref>), making them therapeutically relevant. As for <italic toggle="yes">ADORA2A</italic>, we began by downloading publicly available DNase-seq and histone ChIP-seq data (H3K4me1, H3K4me3, H3K9ac, H3K27ac) from relevant samples, which were remapped to the mm10 genome (Methods). Then, we applied OnTarget to identify candidate CRRs of <italic toggle="yes">PITX3</italic>. We followed the same steps as before with two minor differences: we (i) used a range of ± 50 kb around <italic toggle="yes">Pitx3</italic> when defining the genomic window (i.e. mm10:chr19:46085685–46198325) and (ii) set the minimum score to identify CRRs to ∼0.414. In this example, OnTarget returned 18 CRRs (Table S3): three promoter-like CRRs, including RR8, which overlapped two TSSs associated with <italic toggle="yes">PITX3</italic> (<xref rid="B26" ref-type="bibr">26</xref>), and 15 enhancers, 11 of which overlapped with predicted NR42A TFBSs, which is a known regulator of <italic toggle="yes">PITX3 in vitro</italic> and <italic toggle="yes">in vivo</italic> (<xref rid="B47" ref-type="bibr">47</xref>). Next, using OnTarget, we combined CRRs 5, 6, 8, 13, 16 and 18 into the MiniPromoter Ple388, and confirmed that its 1702 bp-long sequence did not contain any of the cloning restriction sites (i.e. <italic toggle="yes">Asc</italic>l and <italic toggle="yes">Fse</italic>I). Following synthesis, cloning, and packaging, we characterized Ple388 and Ple253, the latter is a previous MiniPromoter that we had manually designed based on <italic toggle="yes">PITX3</italic> (<xref rid="B2" ref-type="bibr">2</xref>), for their ability to drive cell-type-specific EmGFP expression in the substantia nigra (Methods). Even though the choice of delivery method and capsid ensured widespread transduction, the manual design Ple253 failed to induce any expression in the brain (Figure <xref rid="F2" ref-type="fig">2</xref>, bottom-right panel). In contrast, the OnTarget design Ple388 showed strong and specific expression in the substantia nigra (Figure <xref rid="F2" ref-type="fig">2</xref>, bottom-left panel), which is the location of the target dopaminergic neurons.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>DISCUSSION</title>
    <p>We have developed OnTarget, a webserver that enables the design of MiniPromoters for gene expression delivery in specific biological contexts. This system has been applied to two cell types with therapeutic relevance. We evaluated the specificity of the resulting promoters by comparing their expression to those of manually designed alternatives derived from the same genes, confirming the efficacy of OnTarget for designing highly specific MiniPromoters for targeted gene expression.</p>
    <p>The utility of OnTarget extends beyond the design of MiniPromoters. It can also identify CRRs in specific genomic loci of up to 250 kb, making it a valuable tool for a broader range of users. Identification of CRRs benefits from user-provided high-quality genomic evidence relevant to their target cells. While the database underlying OnTarget supports CRR identification based on conservation alone (as in (<xref rid="B1" ref-type="bibr">1</xref>)), users can also provide their own genomic evidence to identify CRRs with cell-type-specificity. For instance, as multiome data becomes more accessible in single-cell studies, such as joint profiling of scATAC-seq and scRNA-seq (<xref rid="B48" ref-type="bibr">48</xref>), users will increasingly have access to such data relevant to their target cells.</p>
    <p>The OnTarget parameters can affect the quality and size of the CRRs identified, most notably the minimum score threshold. During identification of CRRs, OnTarget creates an array with each position corresponding to a nucleotide in the genomic window. Each nucleotide in the array is then scored between 0 and 1, where a score of 1 indicates that the nucleotide overlaps with the greatest amount of genomic evidence, while a score of 0 indicates that the nucleotide overlaps with little (or none) of the genomic evidence. Internal benchmarks revealed that the nucleotide score distribution within the array is typically right-skewed, meaning that most nucleotides have low scores and only a few have high scores (Figure S1). We set the default threshold of 0.5 to ensure that the nucleotides included in the final CRRs would overlap, at least partially, with genomic evidence provided by the user. As properties vary greatly between genes, users may need to adjust this parameter to generate more or less candidate CRRs.</p>
    <p>While there are supervised approaches to predict tissue-specific CRRs (e.g. (<xref rid="B31" ref-type="bibr">31</xref>)), OnTarget uses an unweighted scoring system: each type of data is given equal weight during the identification of CRRs. In our experience, allowing users to select their own data is crucial when designing MiniPromoters. This is because the quality of available data can vary greatly between different tissues. As such, implementing a machine learning process within OnTarget that would be suitable for all scenarios seemed ill-advised. Instead, if users wish to utilize more advanced methods, they can generate and upload their own datasets with CRR-based predictions from deep learning models.</p>
    <p>With the advent of artificial intelligence (AI), it is becoming possible to generate compact promoters <italic toggle="yes">in silico</italic>. For instance, Lawler <italic toggle="yes">et al.</italic> used a machine learning model trained on cell-type-specific genomic evidence to prioritize enhancers based on their predicted cell-type-specificity and experimentally validated two of them <italic toggle="yes">in vivo</italic> (<xref rid="B49" ref-type="bibr">49</xref>). In a recent preprint, Taskiran <italic toggle="yes">et al.</italic> describe three different approaches to designing enhancers using models trained on cell-type-specific genomic evidence (<xref rid="B50" ref-type="bibr">50</xref>): directed evolution (i.e. inserting mutations in randomly generated sequences until their predicted cell-type-specificity is maximized), motif implantation (i.e. embedding motifs of TFs that regulate the target cells within random sequences with optimized orientation and spacing), and a generative approach (i.e. a second model is trained that creates artificial sequences predicted to be cell-type-specific by the first model). Although AI-based approaches show great potential, motif implantation still performs as well as the best methods. As generative methods continue to evolve and improve, OnTarget already provides users with the ability to identify endogenous CRRs that have the potential to deliver the desired expression characteristics.</p>
    <p>At present, OnTarget requires a large amount of user input, from selecting a gene with a desirable expression pattern to providing cell-type-specific genomic evidence, making it one tool within a larger workflow for designing promoters. Future development will allow users to choose genes with a desirable pattern of expression, access public data repositories such as ENCODE (<xref rid="B31" ref-type="bibr">31</xref>) for selecting genomic evidence, and improve the visualization.</p>
  </sec>
  <sec sec-type="data-availability" id="SEC5">
    <title>DATA AVAILABILITY</title>
    <p>OnTarget is hosted on a virtual webserver at <ext-link xlink:href="http://ontarget.cmmt.ubc.ca" ext-link-type="uri">http://ontarget.cmmt.ubc.ca</ext-link> with 20 GB of RAM and 12 Intel Xeon E7540 processors (2.00 GHz, 4 cores and 8 threads) running on CentOS 7. The code for OnTarget is available on GitHub (<ext-link xlink:href="https://github.com/wassermanlab/OnTarget" ext-link-type="uri">https://github.com/wassermanlab/OnTarget</ext-link> and <ext-link xlink:href="https://doi.org/10.5281/zenodo.7871189" ext-link-type="uri">https://doi.org/10.5281/zenodo.7871189</ext-link>). The bash scripts that download and process the genomic evidence for the <italic toggle="yes">ADORA2A</italic> and <italic toggle="yes">PITX3</italic> examples, the evidence itself, and the results from OnTarget are also included in the repository (<ext-link xlink:href="https://github.com/wassermanlab/OnTarget/tree/master/data/examples;" ext-link-type="uri">https://github.com/wassermanlab/OnTarget/tree/master/data/examples;</ext-link> one folder per example). The code for GUD has been deposited on a separate GitHub repository (<ext-link xlink:href="https://github.com/wassermanlab/GUD" ext-link-type="uri">https://github.com/wassermanlab/GUD</ext-link> and <ext-link xlink:href="https://doi.org/10.5281/zenodo.7871278" ext-link-type="uri">https://doi.org/10.5281/zenodo.7871278</ext-link>). GUD is hosted with OnTarget for local accessibility, and runs on MariaDB Server (version 5.5.60). All MiniPromoter sequences used in this work are provided in the Supplementary Data.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>gkad375_Supplemental_Files</label>
      <media xlink:href="gkad375_supplemental_files.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>ACKNOWLEDGEMENTS</title>
    <p>We thank our collaborators Alissandra de Moura Gomes, Diane Choi, as well as Drs Terri L. Petkau, Adriana Galvan, Blair R. Leavitt, and Yoland Smith for providing useful feedback. We thank Dora Pak and Jonathan Chang for administrative and IT support, respectively.</p>
  </ack>
  <sec id="SEC6">
    <title>SUPPLEMENTARY DATA</title>
    <p><ext-link xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkad375#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC7">
    <title>FUNDING</title>
    <p>Genome Canada and the Canadian Institutes of Health Research [OnTarget grants: 255ONT and BOP-149430]; National Science and Engineering Research Council of Canada [Discovery Grant: RGPIN-2017-06824]; Weston Brain Institute. Funding for open access charge: National Science and Engineering Research Council of Canada [Discovery Grant: RGPIN-2017-06824].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Portales-Casamar</surname><given-names>E.</given-names></string-name>, <string-name><surname>Swanson</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L.</given-names></string-name>, <string-name><surname>de Leeuw</surname><given-names>C.N.</given-names></string-name>, <string-name><surname>Banks</surname><given-names>K.G.</given-names></string-name>, <string-name><surname>Ho Sui</surname><given-names>S.J.</given-names></string-name>, <string-name><surname>Fulton</surname><given-names>D.L.</given-names></string-name>, <string-name><surname>Ali</surname><given-names>J.</given-names></string-name>, <string-name><surname>Amirabbasi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Arenillas</surname><given-names>D.J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A regulatory toolbox of MiniPromoters to drive selective expression in the brain</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2010</year>; <volume>107</volume>:<fpage>16589</fpage>–<lpage>16594</lpage>.<pub-id pub-id-type="pmid">20807748</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Korecki</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Cueva-Vargas</surname><given-names>J.L.</given-names></string-name>, <string-name><surname>Fornes</surname><given-names>O.</given-names></string-name>, <string-name><surname>Agostinone</surname><given-names>J.</given-names></string-name>, <string-name><surname>Farkas</surname><given-names>R.A.</given-names></string-name>, <string-name><surname>Hickmott</surname><given-names>J.W.</given-names></string-name>, <string-name><surname>Lam</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Mathelier</surname><given-names>A.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>M.</given-names></string-name>, <string-name><surname>Wasserman</surname><given-names>W.W.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Human MiniPromoters for ocular-rAAV expression in ON bipolar, cone, corneal, endothelial, Müller glial, and PAX6 cells</article-title>. <source>Gene Ther.</source><year>2021</year>; <volume>28</volume>:<fpage>351</fpage>–<lpage>372</lpage>.<pub-id pub-id-type="pmid">33531684</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rodrigues</surname><given-names>G.A.</given-names></string-name>, <string-name><surname>Shalaev</surname><given-names>E.</given-names></string-name>, <string-name><surname>Karami</surname><given-names>T.K.</given-names></string-name>, <string-name><surname>Cunningham</surname><given-names>J.</given-names></string-name>, <string-name><surname>Slater</surname><given-names>N.K.H.</given-names></string-name>, <string-name><surname>Rivers</surname><given-names>H.M.</given-names></string-name></person-group><article-title>Pharmaceutical development of AAV-based gene therapy products for the eye</article-title>. <source>Pharm. Res.</source><year>2018</year>; <volume>36</volume>:<fpage>29</fpage>.<pub-id pub-id-type="pmid">30591984</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Domenger</surname><given-names>C.</given-names></string-name>, <string-name><surname>Grimm</surname><given-names>D</given-names></string-name></person-group><article-title>Next-generation AAV vectors-do not judge a virus (only) by its cover</article-title>. <source>Hum. Mol. Genet.</source><year>2019</year>; <volume>28</volume>:<fpage>R3</fpage>–<lpage>R14</lpage>.<pub-id pub-id-type="pmid">31261383</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maguire</surname><given-names>A.M.</given-names></string-name>, <string-name><surname>Simonelli</surname><given-names>F.</given-names></string-name>, <string-name><surname>Pierce</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Pugh</surname><given-names>E.N.</given-names></string-name>, <string-name><surname>Mingozzi</surname><given-names>F.</given-names></string-name>, <string-name><surname>Bennicelli</surname><given-names>J.</given-names></string-name>, <string-name><surname>Banfi</surname><given-names>S.</given-names></string-name>, <string-name><surname>Marshall</surname><given-names>K.A.</given-names></string-name>, <string-name><surname>Testa</surname><given-names>F.</given-names></string-name>, <string-name><surname>Surace</surname><given-names>E.M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Safety and efficacy of gene transfer for Leber's congenital amaurosis</article-title>. <source>N. Engl. J. Med.</source><year>2008</year>; <volume>358</volume>:<fpage>2240</fpage>–<lpage>2248</lpage>.<pub-id pub-id-type="pmid">18441370</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nathwani</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Reiss</surname><given-names>U.M.</given-names></string-name>, <string-name><surname>Tuddenham</surname><given-names>E.G.D.</given-names></string-name>, <string-name><surname>Rosales</surname><given-names>C.</given-names></string-name>, <string-name><surname>Chowdary</surname><given-names>P.</given-names></string-name>, <string-name><surname>McIntosh</surname><given-names>J.</given-names></string-name>, <string-name><surname>Della Peruta</surname><given-names>M.</given-names></string-name>, <string-name><surname>Lheriteau</surname><given-names>E.</given-names></string-name>, <string-name><surname>Patel</surname><given-names>N.</given-names></string-name>, <string-name><surname>Raj</surname><given-names>D.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Long-term safety and efficacy of factor IX gene therapy in hemophilia B</article-title>. <source>N. Engl. J. Med.</source><year>2014</year>; <volume>371</volume>:<fpage>1994</fpage>–<lpage>2004</lpage>.<pub-id pub-id-type="pmid">25409372</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kotterman</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Schaffer</surname><given-names>D.V.</given-names></string-name></person-group><article-title>Engineering adeno-associated viruses for clinical gene therapy</article-title>. <source>Nat. Rev. Genet.</source><year>2014</year>; <volume>15</volume>:<fpage>445</fpage>–<lpage>451</lpage>.<pub-id pub-id-type="pmid">24840552</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>C.</given-names></string-name>, <string-name><surname>Samulski</surname><given-names>R.J.</given-names></string-name></person-group><article-title>Engineering adeno-associated virus vectors for gene therapy</article-title>. <source>Nat. Rev. Genet.</source><year>2020</year>; <volume>21</volume>:<fpage>255</fpage>–<lpage>272</lpage>.<pub-id pub-id-type="pmid">32042148</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Colosi</surname><given-names>P.</given-names></string-name></person-group><article-title>Effect of genome size on AAV vector packaging</article-title>. <source>Mol. Ther.</source><year>2010</year>; <volume>18</volume>:<fpage>80</fpage>–<lpage>86</lpage>.<pub-id pub-id-type="pmid">19904234</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Leeuw</surname><given-names>C.N.</given-names></string-name>, <string-name><surname>Dyka</surname><given-names>F.M.</given-names></string-name>, <string-name><surname>Boye</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Laprise</surname><given-names>S.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>M.</given-names></string-name>, <string-name><surname>Chou</surname><given-names>A.Y.</given-names></string-name>, <string-name><surname>Borretta</surname><given-names>L.</given-names></string-name>, <string-name><surname>McInerny</surname><given-names>S.C.</given-names></string-name>, <string-name><surname>Banks</surname><given-names>K.G.</given-names></string-name>, <string-name><surname>Portales-Casamar</surname><given-names>E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Targeted CNS delivery using Human MiniPromoters and demonstrated compatibility with adeno-associated viral vectors</article-title>. <source>Mol. Ther. Methods Clin. Dev.</source><year>2014</year>; <volume>1</volume>:<fpage>5</fpage>.</mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Leeuw</surname><given-names>C.N.</given-names></string-name>, <string-name><surname>Korecki</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Berry</surname><given-names>G.E.</given-names></string-name>, <string-name><surname>Hickmott</surname><given-names>J.W.</given-names></string-name>, <string-name><surname>Lam</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Lengyell</surname><given-names>T.C.</given-names></string-name>, <string-name><surname>Bonaguro</surname><given-names>R.J.</given-names></string-name>, <string-name><surname>Borretta</surname><given-names>L.J.</given-names></string-name>, <string-name><surname>Chopra</surname><given-names>V.</given-names></string-name>, <string-name><surname>Chou</surname><given-names>A.Y.</given-names></string-name><etal>et al</etal>.</person-group><article-title>rAAV-compatible MiniPromoters for restricted expression in the brain and eye</article-title>. <source>Mol. Brain</source>. <year>2016</year>; <volume>9</volume>:<fpage>52</fpage>.<pub-id pub-id-type="pmid">27164903</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hickmott</surname><given-names>J.W.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>C.-Y.</given-names></string-name>, <string-name><surname>Arenillas</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Korecki</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Lam</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Molday</surname><given-names>L.L.</given-names></string-name>, <string-name><surname>Bonaguro</surname><given-names>R.J.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>M.</given-names></string-name>, <string-name><surname>Chou</surname><given-names>A.Y.</given-names></string-name>, <string-name><surname>Mathelier</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>PAX6 MiniPromoters drive restricted expression from rAAV in the adult mouse retina</article-title>. <source>Mol. Ther. Methods Clin. Dev.</source><year>2016</year>; <volume>3</volume>:<fpage>16051</fpage>.<pub-id pub-id-type="pmid">27556059</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Korecki</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Hickmott</surname><given-names>J.W.</given-names></string-name>, <string-name><surname>Lam</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Dreolini</surname><given-names>L.</given-names></string-name>, <string-name><surname>Mathelier</surname><given-names>A.</given-names></string-name>, <string-name><surname>Baker</surname><given-names>O.</given-names></string-name>, <string-name><surname>Kuehne</surname><given-names>C.</given-names></string-name>, <string-name><surname>Bonaguro</surname><given-names>R.J.</given-names></string-name>, <string-name><surname>Smith</surname><given-names>J.</given-names></string-name>, <string-name><surname>Tan</surname><given-names>C.-V.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Twenty-seven Tamoxifen-inducible iCre-driver mouse strains for eye and brain, including seventeen carrying a new inducible-first constitutive-ready Allele</article-title>. <source>Genetics</source>. <year>2019</year>; <volume>211</volume>:<fpage>1155</fpage>–<lpage>1177</lpage>.<pub-id pub-id-type="pmid">30765420</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Simpson</surname><given-names>E.M.</given-names></string-name>, <string-name><surname>Korecki</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Fornes</surname><given-names>O.</given-names></string-name>, <string-name><surname>McGill</surname><given-names>T.J.</given-names></string-name>, <string-name><surname>Cueva-Vargas</surname><given-names>J.L.</given-names></string-name>, <string-name><surname>Agostinone</surname><given-names>J.</given-names></string-name>, <string-name><surname>Farkas</surname><given-names>R.A.</given-names></string-name>, <string-name><surname>Hickmott</surname><given-names>J.W.</given-names></string-name>, <string-name><surname>Lam</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Mathelier</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>New MiniPromoter Ple345 (NEFL) drives strong and specific expression in retinal ganglion cells of mouse and primate retina</article-title>. <source>Hum. Gene Ther.</source><year>2019</year>; <volume>30</volume>:<fpage>257</fpage>–<lpage>272</lpage>.<pub-id pub-id-type="pmid">30062914</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Barbacioru</surname><given-names>C.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Nordman</surname><given-names>E.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>C.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>N.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Bodeau</surname><given-names>J.</given-names></string-name>, <string-name><surname>Tuch</surname><given-names>B.B.</given-names></string-name>, <string-name><surname>Siddiqui</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>mRNA-seq whole-transcriptome analysis of a single cell</article-title>. <source>Nat. Methods</source>. <year>2009</year>; <volume>6</volume>:<fpage>377</fpage>–<lpage>382</lpage>.<pub-id pub-id-type="pmid">19349980</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Blanchette</surname><given-names>M.</given-names></string-name>, <string-name><surname>Kent</surname><given-names>W.J.</given-names></string-name>, <string-name><surname>Riemer</surname><given-names>C.</given-names></string-name>, <string-name><surname>Elnitski</surname><given-names>L.</given-names></string-name>, <string-name><surname>Smit</surname><given-names>A.F.A.</given-names></string-name>, <string-name><surname>Roskin</surname><given-names>K.M.</given-names></string-name>, <string-name><surname>Baertsch</surname><given-names>R.</given-names></string-name>, <string-name><surname>Rosenbloom</surname><given-names>K.</given-names></string-name>, <string-name><surname>Clawson</surname><given-names>H.</given-names></string-name>, <string-name><surname>Green</surname><given-names>E.D.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Aligning multiple genomic sequences with the threaded blockset aligner</article-title>. <source>Genome Res.</source><year>2004</year>; <volume>14</volume>:<fpage>708</fpage>–<lpage>715</lpage>.<pub-id pub-id-type="pmid">15060014</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nassar</surname><given-names>L.R.</given-names></string-name>, <string-name><surname>Barber</surname><given-names>G.P.</given-names></string-name>, <string-name><surname>Benet-Pagès</surname><given-names>A.</given-names></string-name>, <string-name><surname>Casper</surname><given-names>J.</given-names></string-name>, <string-name><surname>Clawson</surname><given-names>H.</given-names></string-name>, <string-name><surname>Diekhans</surname><given-names>M.</given-names></string-name>, <string-name><surname>Fischer</surname><given-names>C.</given-names></string-name>, <string-name><surname>Gonzalez</surname><given-names>J.N.</given-names></string-name>, <string-name><surname>Hinrichs</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>B.T.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The UCSC Genome Browser database: 2023 update</article-title>. <source>Nucleic Acids Res.</source><year>2023</year>; <volume>51</volume>:<fpage>D1188</fpage>–<lpage>D1195</lpage>.<pub-id pub-id-type="pmid">36420891</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Leary</surname><given-names>N.A.</given-names></string-name>, <string-name><surname>Wright</surname><given-names>M.W.</given-names></string-name>, <string-name><surname>Brister</surname><given-names>J.R.</given-names></string-name>, <string-name><surname>Ciufo</surname><given-names>S.</given-names></string-name>, <string-name><surname>Haddad</surname><given-names>D.</given-names></string-name>, <string-name><surname>McVeigh</surname><given-names>R.</given-names></string-name>, <string-name><surname>Rajput</surname><given-names>B.</given-names></string-name>, <string-name><surname>Robbertse</surname><given-names>B.</given-names></string-name>, <string-name><surname>Smith-White</surname><given-names>B.</given-names></string-name>, <string-name><surname>Ako-Adjei</surname><given-names>D.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>; <volume>44</volume>:<fpage>D733</fpage>–<lpage>D745</lpage>.<pub-id pub-id-type="pmid">26553804</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harris</surname><given-names>C.R.</given-names></string-name>, <string-name><surname>Millman</surname><given-names>K.J.</given-names></string-name>, <string-name><surname>van der Walt</surname><given-names>S.J.</given-names></string-name>, <string-name><surname>Gommers</surname><given-names>R.</given-names></string-name>, <string-name><surname>Virtanen</surname><given-names>P.</given-names></string-name>, <string-name><surname>Cournapeau</surname><given-names>D.</given-names></string-name>, <string-name><surname>Wieser</surname><given-names>E.</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>J.</given-names></string-name>, <string-name><surname>Berg</surname><given-names>S.</given-names></string-name>, <string-name><surname>Smith</surname><given-names>N.J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Array programming with NumPy</article-title>. <source>Nature</source>. <year>2020</year>; <volume>585</volume>:<fpage>357</fpage>–<lpage>362</lpage>.<pub-id pub-id-type="pmid">32939066</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Creyghton</surname><given-names>M.P.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>A.W.</given-names></string-name>, <string-name><surname>Welstead</surname><given-names>G.G.</given-names></string-name>, <string-name><surname>Kooistra</surname><given-names>T.</given-names></string-name>, <string-name><surname>Carey</surname><given-names>B.W.</given-names></string-name>, <string-name><surname>Steine</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Hanna</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lodato</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Frampton</surname><given-names>G.M.</given-names></string-name>, <string-name><surname>Sharp</surname><given-names>P.A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Histone H3K27ac separates active from poised enhancers and predicts developmental state</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2010</year>; <volume>107</volume>:<fpage>21931</fpage>–<lpage>21936</lpage>.<pub-id pub-id-type="pmid">21106759</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pedregosa</surname><given-names>F.</given-names></string-name>, <string-name><surname>Varoquaux</surname><given-names>G.</given-names></string-name>, <string-name><surname>Gramfort</surname><given-names>A.</given-names></string-name>, <string-name><surname>Michel</surname><given-names>V.</given-names></string-name>, <string-name><surname>Thirion</surname><given-names>B.</given-names></string-name>, <string-name><surname>Grisel</surname><given-names>O.</given-names></string-name>, <string-name><surname>Blondel</surname><given-names>M.</given-names></string-name>, <string-name><surname>Prettenhofer</surname><given-names>P.</given-names></string-name>, <string-name><surname>Weiss</surname><given-names>R.</given-names></string-name>, <string-name><surname>Dubourg</surname><given-names>V.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Scikit-learn: machine learning in Python</article-title>. <source>J. Mach. Learn Res.</source><year>2011</year>; <volume>12</volume>:<fpage>2825</fpage>–<lpage>2830</lpage>.</mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fornes</surname><given-names>O.</given-names></string-name>, <string-name><surname>Castro-Mondragon</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Khan</surname><given-names>A.</given-names></string-name>, <string-name><surname>van der Lee</surname><given-names>R.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Richmond</surname><given-names>P.A.</given-names></string-name>, <string-name><surname>Modi</surname><given-names>B.P.</given-names></string-name>, <string-name><surname>Correard</surname><given-names>S.</given-names></string-name>, <string-name><surname>Gheorghe</surname><given-names>M.</given-names></string-name>, <string-name><surname>Baranašić</surname><given-names>D.</given-names></string-name><etal>et al</etal>.</person-group><article-title>JASPAR 2020: update of the open-access database of transcription factor binding profiles</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D87</fpage>–<lpage>D92</lpage>.<pub-id pub-id-type="pmid">31701148</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hinrichs</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Karolchik</surname><given-names>D.</given-names></string-name>, <string-name><surname>Baertsch</surname><given-names>R.</given-names></string-name>, <string-name><surname>Barber</surname><given-names>G.P.</given-names></string-name>, <string-name><surname>Bejerano</surname><given-names>G.</given-names></string-name>, <string-name><surname>Clawson</surname><given-names>H.</given-names></string-name>, <string-name><surname>Diekhans</surname><given-names>M.</given-names></string-name>, <string-name><surname>Furey</surname><given-names>T.S.</given-names></string-name>, <string-name><surname>Harte</surname><given-names>R.A.</given-names></string-name>, <string-name><surname>Hsu</surname><given-names>F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The UCSC Genome Browser Database: update 2006</article-title>. <source>Nucleic Acids Res.</source><year>2006</year>; <volume>34</volume>:<fpage>D590</fpage>–<lpage>D598</lpage>.<pub-id pub-id-type="pmid">16381938</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robinson</surname><given-names>J.T.</given-names></string-name>, <string-name><surname>Thorvaldsdóttir</surname><given-names>H.</given-names></string-name>, <string-name><surname>Winckler</surname><given-names>W.</given-names></string-name>, <string-name><surname>Guttman</surname><given-names>M.</given-names></string-name>, <string-name><surname>Lander</surname><given-names>E.S.</given-names></string-name>, <string-name><surname>Getz</surname><given-names>G.</given-names></string-name>, <string-name><surname>Mesirov</surname><given-names>J.P.</given-names></string-name></person-group><article-title>Integrative genomics viewer</article-title>. <source>Nat. Biotechnol.</source><year>2011</year>; <volume>29</volume>:<fpage>24</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">21221095</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andersson</surname><given-names>R.</given-names></string-name>, <string-name><surname>Gebhard</surname><given-names>C.</given-names></string-name>, <string-name><surname>Miguel-Escalada</surname><given-names>I.</given-names></string-name>, <string-name><surname>Hoof</surname><given-names>I.</given-names></string-name>, <string-name><surname>Bornholdt</surname><given-names>J.</given-names></string-name>, <string-name><surname>Boyd</surname><given-names>M.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>X.</given-names></string-name>, <string-name><surname>Schmidl</surname><given-names>C.</given-names></string-name>, <string-name><surname>Suzuki</surname><given-names>T.</given-names></string-name><etal>et al</etal>.</person-group><article-title>An atlas of active enhancers across human cell types and tissues</article-title>. <source>Nature</source>. <year>2014</year>; <volume>507</volume>:<fpage>455</fpage>–<lpage>461</lpage>.<pub-id pub-id-type="pmid">24670763</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>FANTOM Consortium and the RIKEN PMI and CLST (DGT)</collab><string-name><surname>Forrest</surname><given-names>A.R.R.</given-names></string-name>, <string-name><surname>Kawaji</surname><given-names>H.</given-names></string-name>, <string-name><surname>Rehli</surname><given-names>M.</given-names></string-name>, <string-name><surname>Baillie</surname><given-names>J.K.</given-names></string-name>, <string-name><surname>de Hoon</surname><given-names>M.J.L.</given-names></string-name>, <string-name><surname>Haberle</surname><given-names>V.</given-names></string-name>, <string-name><surname>Lassmann</surname><given-names>T.</given-names></string-name>, <string-name><surname>Kulakovskiy</surname><given-names>I.V.</given-names></string-name>, <string-name><surname>Lizio</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A promoter-level mammalian expression atlas</article-title>. <source>Nature</source>. <year>2014</year>; <volume>507</volume>:<fpage>462</fpage>–<lpage>470</lpage>.<pub-id pub-id-type="pmid">24670764</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Danko</surname><given-names>C.G.</given-names></string-name>, <string-name><surname>Hyland</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Core</surname><given-names>L.J.</given-names></string-name>, <string-name><surname>Martins</surname><given-names>A.L.</given-names></string-name>, <string-name><surname>Waters</surname><given-names>C.T.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>H.W.</given-names></string-name>, <string-name><surname>Cheung</surname><given-names>V.G.</given-names></string-name>, <string-name><surname>Kraus</surname><given-names>W.L.</given-names></string-name>, <string-name><surname>Lis</surname><given-names>J.T.</given-names></string-name>, <string-name><surname>Siepel</surname><given-names>A.</given-names></string-name></person-group><article-title>Identification of active transcriptional regulatory elements from GRO-seq data</article-title>. <source>Nat. Methods</source>. <year>2015</year>; <volume>12</volume>:<fpage>433</fpage>–<lpage>438</lpage>.<pub-id pub-id-type="pmid">25799441</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boyle</surname><given-names>A.P.</given-names></string-name>, <string-name><surname>Davis</surname><given-names>S.</given-names></string-name>, <string-name><surname>Shulha</surname><given-names>H.P.</given-names></string-name>, <string-name><surname>Meltzer</surname><given-names>P.</given-names></string-name>, <string-name><surname>Margulies</surname><given-names>E.H.</given-names></string-name>, <string-name><surname>Weng</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Furey</surname><given-names>T.S.</given-names></string-name>, <string-name><surname>Crawford</surname><given-names>G.E.</given-names></string-name></person-group><article-title>High-resolution mapping and characterization of open chromatin across the genome</article-title>. <source>Cell</source>. <year>2008</year>; <volume>132</volume>:<fpage>311</fpage>–<lpage>322</lpage>.<pub-id pub-id-type="pmid">18243105</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Buenrostro</surname><given-names>J.D.</given-names></string-name>, <string-name><surname>Giresi</surname><given-names>P.G.</given-names></string-name>, <string-name><surname>Zaba</surname><given-names>L.C.</given-names></string-name>, <string-name><surname>Chang</surname><given-names>H.Y.</given-names></string-name>, <string-name><surname>Greenleaf</surname><given-names>W.J.</given-names></string-name></person-group><article-title>Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position</article-title>. <source>Nat. Methods</source>. <year>2013</year>; <volume>10</volume>:<fpage>1213</fpage>–<lpage>1218</lpage>.<pub-id pub-id-type="pmid">24097267</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Johnson</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Mortazavi</surname><given-names>A.</given-names></string-name>, <string-name><surname>Myers</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>Wold</surname><given-names>B.</given-names></string-name></person-group><article-title>Genome-wide mapping of in vivo protein-DNA interactions</article-title>. <source>Science</source>. <year>2007</year>; <volume>316</volume>:<fpage>1497</fpage>–<lpage>1502</lpage>.<pub-id pub-id-type="pmid">17540862</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>ENCODE Project Consortium</collab><string-name><surname>Moore</surname><given-names>J.E.</given-names></string-name>, <string-name><surname>Purcaro</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Pratt</surname><given-names>H.E.</given-names></string-name>, <string-name><surname>Epstein</surname><given-names>C.B.</given-names></string-name>, <string-name><surname>Shoresh</surname><given-names>N.</given-names></string-name>, <string-name><surname>Adrian</surname><given-names>J.</given-names></string-name>, <string-name><surname>Kawli</surname><given-names>T.</given-names></string-name>, <string-name><surname>Davis</surname><given-names>C.A.</given-names></string-name>, <string-name><surname>Dobin</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Expanded encyclopaedias of DNA elements in the human and mouse genomes</article-title>. <source>Nature</source>. <year>2020</year>; <volume>583</volume>:<fpage>699</fpage>–<lpage>710</lpage>.<pub-id pub-id-type="pmid">32728249</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Long</surname><given-names>H.S.</given-names></string-name>, <string-name><surname>Greenaway</surname><given-names>S.</given-names></string-name>, <string-name><surname>Powell</surname><given-names>G.</given-names></string-name>, <string-name><surname>Mallon</surname><given-names>A.-M.</given-names></string-name>, <string-name><surname>Lindgren</surname><given-names>C.M.</given-names></string-name>, <string-name><surname>Simon</surname><given-names>M.M.</given-names></string-name></person-group><article-title>Making sense of the linear genome, gene function and tads</article-title>. <source>Epigenetics Chromatin</source>. <year>2022</year>; <volume>15</volume>:<fpage>4</fpage>.<pub-id pub-id-type="pmid">35090532</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vincze</surname><given-names>T.</given-names></string-name>, <string-name><surname>Posfai</surname><given-names>J.</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>R.J.</given-names></string-name></person-group><article-title>NEBcutter: a program to cleave DNA with restriction enzymes</article-title>. <source>Nucleic Acids Res.</source><year>2003</year>; <volume>31</volume>:<fpage>3688</fpage>–<lpage>3691</lpage>.<pub-id pub-id-type="pmid">12824395</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fullard</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Hauberg</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Bendl</surname><given-names>J.</given-names></string-name>, <string-name><surname>Egervari</surname><given-names>G.</given-names></string-name>, <string-name><surname>Cirnaru</surname><given-names>M.-D.</given-names></string-name>, <string-name><surname>Reach</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Motl</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ehrlich</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Hurd</surname><given-names>Y.L.</given-names></string-name>, <string-name><surname>Roussos</surname><given-names>P.</given-names></string-name></person-group><article-title>An atlas of chromatin accessibility in the adult human brain</article-title>. <source>Genome Res.</source><year>2018</year>; <volume>28</volume>:<fpage>1243</fpage>–<lpage>1252</lpage>.<pub-id pub-id-type="pmid">29945882</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kent</surname><given-names>W.J.</given-names></string-name>, <string-name><surname>Zweig</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Barber</surname><given-names>G.</given-names></string-name>, <string-name><surname>Hinrichs</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Karolchik</surname><given-names>D</given-names></string-name></person-group><article-title>BigWig and BigBed: enabling browsing of large distributed datasets</article-title>. <source>Bioinforma. Oxf. Engl.</source><year>2010</year>; <volume>26</volume>:<fpage>2204</fpage>–<lpage>2207</lpage>.</mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>T.</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>C.A.</given-names></string-name>, <string-name><surname>Eeckhoute</surname><given-names>J.</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Bernstein</surname><given-names>B.E.</given-names></string-name>, <string-name><surname>Nusbaum</surname><given-names>C.</given-names></string-name>, <string-name><surname>Myers</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>Brown</surname><given-names>M.</given-names></string-name>, <string-name><surname>Li</surname><given-names>W.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Model-based analysis of ChIP-Seq (MACS)</article-title>. <source>Genome Biol.</source><year>2008</year>; <volume>9</volume>:<fpage>R137</fpage>.<pub-id pub-id-type="pmid">18798982</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feng</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wilkinson</surname><given-names>M.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Purushothaman</surname><given-names>I.</given-names></string-name>, <string-name><surname>Ferguson</surname><given-names>D.</given-names></string-name>, <string-name><surname>Vialou</surname><given-names>V.</given-names></string-name>, <string-name><surname>Maze</surname><given-names>I.</given-names></string-name>, <string-name><surname>Shao</surname><given-names>N.</given-names></string-name>, <string-name><surname>Kennedy</surname><given-names>P.</given-names></string-name>, <string-name><surname>Koo</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Chronic cocaine-regulated epigenomic changes in mouse nucleus accumbens</article-title>. <source>Genome Biol.</source><year>2014</year>; <volume>15</volume>:<fpage>R65</fpage>.<pub-id pub-id-type="pmid">24758366</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>von Schimmelmann</surname><given-names>M.</given-names></string-name>, <string-name><surname>Feinberg</surname><given-names>P.A.</given-names></string-name>, <string-name><surname>Sullivan</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Ku</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Badimon</surname><given-names>A.</given-names></string-name>, <string-name><surname>Duff</surname><given-names>M.K.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Lachmann</surname><given-names>A.</given-names></string-name>, <string-name><surname>Dewell</surname><given-names>S.</given-names></string-name>, <string-name><surname>Ma’ayan</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Polycomb repressive complex 2 (PRC2) silences genes responsible for neurodegeneration</article-title>. <source>Nat. Neurosci.</source><year>2016</year>; <volume>19</volume>:<fpage>1321</fpage>–<lpage>1330</lpage>.<pub-id pub-id-type="pmid">27526204</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Chan</surname><given-names>K.Y.</given-names></string-name>, <string-name><surname>Tobey</surname><given-names>I.G.</given-names></string-name>, <string-name><surname>Chan</surname><given-names>Y.A.</given-names></string-name>, <string-name><surname>Poterba</surname><given-names>T.</given-names></string-name>, <string-name><surname>Boutros</surname><given-names>C.L.</given-names></string-name>, <string-name><surname>Balazs</surname><given-names>A.B.</given-names></string-name>, <string-name><surname>Daneman</surname><given-names>R.</given-names></string-name>, <string-name><surname>Bloom</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Seed</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids</article-title>. <source>PLoS One</source>. <year>2019</year>; <volume>14</volume>:<fpage>e0225206</fpage>.<pub-id pub-id-type="pmid">31725765</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gokce</surname><given-names>O.</given-names></string-name>, <string-name><surname>Stanley</surname><given-names>G.M.</given-names></string-name>, <string-name><surname>Treutlein</surname><given-names>B.</given-names></string-name>, <string-name><surname>Neff</surname><given-names>N.F.</given-names></string-name>, <string-name><surname>Camp</surname><given-names>J.G.</given-names></string-name>, <string-name><surname>Malenka</surname><given-names>R.C.</given-names></string-name>, <string-name><surname>Rothwell</surname><given-names>P.E.</given-names></string-name>, <string-name><surname>Fuccillo</surname><given-names>M.V.</given-names></string-name>, <string-name><surname>Südhof</surname><given-names>T.C.</given-names></string-name>, <string-name><surname>Quake</surname><given-names>S.R.</given-names></string-name></person-group><article-title>Cellular taxonomy of the mouse striatum as revealed by single-cell RNA-seq</article-title>. <source>Cell Rep.</source><year>2016</year>; <volume>16</volume>:<fpage>1126</fpage>–<lpage>1137</lpage>.<pub-id pub-id-type="pmid">27425622</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tozzi</surname><given-names>A.</given-names></string-name>, <string-name><surname>de Iure</surname><given-names>A.</given-names></string-name>, <string-name><surname>Di Filippo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Tantucci</surname><given-names>M.</given-names></string-name>, <string-name><surname>Costa</surname><given-names>C.</given-names></string-name>, <string-name><surname>Borsini</surname><given-names>F.</given-names></string-name>, <string-name><surname>Ghiglieri</surname><given-names>V.</given-names></string-name>, <string-name><surname>Giampà</surname><given-names>C.</given-names></string-name>, <string-name><surname>Fusco</surname><given-names>F.R.</given-names></string-name>, <string-name><surname>Picconi</surname><given-names>B.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The distinct role of medium spiny neurons and cholinergic interneurons in the D<sub>2</sub>/A<sub>2</sub>A receptor interaction in the striatum: implications for Parkinson's disease</article-title>. <source>J. Neurosci.</source><year>2011</year>; <volume>31</volume>:<fpage>1850</fpage>–<lpage>1862</lpage>.<pub-id pub-id-type="pmid">21289195</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Samad</surname><given-names>T.A.</given-names></string-name>, <string-name><surname>Krezel</surname><given-names>W.</given-names></string-name>, <string-name><surname>Chambon</surname><given-names>P.</given-names></string-name>, <string-name><surname>Borrelli</surname><given-names>E.</given-names></string-name></person-group><article-title>Regulation of dopaminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>1997</year>; <volume>94</volume>:<fpage>14349</fpage>–<lpage>14354</lpage>.<pub-id pub-id-type="pmid">9405615</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Liang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Song</surname><given-names>X.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Lindtner</surname><given-names>S.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Wen</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>G.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>T.</given-names></string-name>, <string-name><surname>Qi</surname><given-names>D.</given-names></string-name><etal>et al</etal>.</person-group><article-title>SP8 and SP9 coordinately promote D2-type medium spiny neuron production by activating Six3 expression</article-title>. <source>Dev. Camb. Engl.</source><year>2018</year>; <volume>145</volume>:<fpage>dev165456</fpage>.</mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nunes</surname><given-names>I.</given-names></string-name>, <string-name><surname>Tovmasian</surname><given-names>L.T.</given-names></string-name>, <string-name><surname>Silva</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>Burke</surname><given-names>R.E.</given-names></string-name>, <string-name><surname>Goff</surname><given-names>S.P.</given-names></string-name></person-group><article-title>Pitx3 is required for development of substantia nigra dopaminergic neurons</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2003</year>; <volume>100</volume>:<fpage>4245</fpage>–<lpage>4250</lpage>.<pub-id pub-id-type="pmid">12655058</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fearnley</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Lees</surname><given-names>A.J.</given-names></string-name></person-group><article-title>Ageing and Parkinson's disease: substantia nigra regional selectivity</article-title>. <source>Biomarkers Brain Inj. Neurol. Disord.</source><year>1991</year>; <volume>114</volume>:<fpage>2283</fpage>–<lpage>2301</lpage>.</mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Hornykiewicz</surname><given-names>O.</given-names></string-name></person-group><person-group person-group-type="editor"><string-name><surname>Riederer</surname><given-names>P.</given-names></string-name>, <string-name><surname>Reichmann</surname><given-names>H.</given-names></string-name>, <string-name><surname>Youdim</surname><given-names>M.B.H.</given-names></string-name>, <string-name><surname>Gerlach</surname><given-names>M.</given-names></string-name></person-group><article-title>The discovery of dopamine deficiency in the parkinsonian brain</article-title>. <source>Parkinson’s Disease and Related Disorders. Journal of Neural Transmission. Supplementa</source>. <year>2006</year>; <volume>70</volume>:<publisher-loc>Vienna</publisher-loc><publisher-name>Springer</publisher-name>.</mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Volpicelli</surname><given-names>F.</given-names></string-name>, <string-name><surname>De Gregorio</surname><given-names>R.</given-names></string-name>, <string-name><surname>Pulcrano</surname><given-names>S.</given-names></string-name>, <string-name><surname>Perrone-Capano</surname><given-names>C.</given-names></string-name>, <string-name><surname>di Porzio</surname><given-names>U.</given-names></string-name>, <string-name><surname>Bellenchi</surname><given-names>G.C.</given-names></string-name></person-group><article-title>Direct regulation of Pitx3 expression by Nurr1 in culture and in developing mouse midbrain</article-title>. <source>PLoS One</source>. <year>2012</year>; <volume>7</volume>:<fpage>e30661</fpage>.<pub-id pub-id-type="pmid">22363463</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cao</surname><given-names>J.</given-names></string-name>, <string-name><surname>Cusanovich</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>Ramani</surname><given-names>V.</given-names></string-name>, <string-name><surname>Aghamirzaie</surname><given-names>D.</given-names></string-name>, <string-name><surname>Pliner</surname><given-names>H.A.</given-names></string-name>, <string-name><surname>Hill</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Daza</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>McFaline-Figueroa</surname><given-names>J.L.</given-names></string-name>, <string-name><surname>Packer</surname><given-names>J.S.</given-names></string-name>, <string-name><surname>Christiansen</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Joint profiling of chromatin accessibility and gene expression in thousands of single cells</article-title>. <source>Science</source>. <year>2018</year>; <volume>361</volume>:<fpage>1380</fpage>–<lpage>1385</lpage>.<pub-id pub-id-type="pmid">30166440</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lawler</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Ramamurthy</surname><given-names>E.</given-names></string-name>, <string-name><surname>Brown</surname><given-names>A.R.</given-names></string-name>, <string-name><surname>Shin</surname><given-names>N.</given-names></string-name>, <string-name><surname>Kim</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Toong</surname><given-names>N.</given-names></string-name>, <string-name><surname>Kaplow</surname><given-names>I.M.</given-names></string-name>, <string-name><surname>Wirthlin</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Phan</surname><given-names>B.N.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Machine learning sequence prioritization for cell type-specific enhancer design</article-title>. <source>Elife</source>. <year>2022</year>; <volume>11</volume>:<fpage>e69571</fpage>.<pub-id pub-id-type="pmid">35576146</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Taskiran</surname><given-names>I.I.</given-names></string-name>, <string-name><surname>Spanier</surname><given-names>K.I.</given-names></string-name>, <string-name><surname>Christiaens</surname><given-names>V.</given-names></string-name>, <string-name><surname>Mauduit</surname><given-names>D.</given-names></string-name>, <string-name><surname>Aerts</surname><given-names>S.</given-names></string-name></person-group><article-title>Cell type directed design of synthetic enhancers</article-title>. <year>2022</year>; <comment>bioRxiv doi:</comment><comment>27 July 2022, preprint: not peer reviewed</comment><pub-id pub-id-type="doi">10.1101/2022.07.26.501466</pub-id>.</mixed-citation>
    </ref>
  </ref-list>
</back>
